Axial: https://linktr.ee/axialxyz
Axial partners with great founders and inventors. We invest in early-stage life sciences companies such as Appia Bio, Seranova Bio, Delix Therapeutics, Simcha Therapeutics, among others often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company . We are excited to be in business with you - email us at info@axialvc.com
Kymab was acquired by Sanofi for >$1B in 2021. It is a case study of developing drugs with high conviction despite patent challenges, competition in the clinic, & trailblazing a new MoA. Founded in 2010 out of Cambridge, UK, Kymab is also an example for every British biotech.
The platform is centered around a transgenic mouse model from the Allan Bradley Lab at the Sanger Institute. Kymab was able to generate a mAb for OX40L (an emerging cancer target) among other immunoregulatory targets https://www.kymab.com/media/uploads/files/Lee_et_al._2014-1.pdf
This technology led to patent challenges from Regeneron, settled in 2020 https://www.kymab.com/media/uploads/files/2020-06-24_Kymab_UK_Supreme_Court_Press_ReleaseFINAL.pdf
Despite operating in this backdrop, Kymab was able to drive their lead to the clinic. In 2020, they reported phase 2a data in severe atopic dermatitis meeting both primary endpoints.
In an IO boom where companies were focusing on increasing/decreasing T-cell subpopulations. Kymab focused on balancing them. Driving their clinical success, & partnership discussions leading to Sanofi’s (new CEO wanted to do deals) acquisition https://www.sanofi.com/en/media-room/press-releases/2021/2021-01-11-07-30-00-2155914